NASDAQ:NUVA - NuVasive Stock Price, Forecast & News

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings data on Thursday, February, 20th. The medical device company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.09. The medical device company earned $310.40 million during the quarter, compared to analyst estimates of $304.93 million. NuVasive had a net margin of 5.58% and a return on equity of 15.10%. NuVasive's revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.69 EPS. View NuVasive's Earnings History.

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for NuVasive.

NuVasive issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus estimate of $2.60. The company issued revenue guidance of $1.21-1.24 billion, compared to the consensus revenue estimate of $1.23 billion.

16 analysts have issued 12-month target prices for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they expect NuVasive's share price to reach $79.67 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for NuVasive.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuVasive.

News coverage about NUVA stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuVasive earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for NuVasive.

NuVasive saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,200,000 shares, an increase of 7.7% from the January 15th total of 3,900,000 shares. Based on an average trading volume of 497,800 shares, the short-interest ratio is presently 8.4 days. Currently, 8.1% of the shares of the company are sold short. View NuVasive's Current Options Chain.

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Starbucks (SBUX), Alibaba Group (BABA), Global Sources Ltd. (Bermuda) (GSOL), Intel (INTC), Celgene (CELG) and Gilead Sciences (GILD).

NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Anchor Capital Advisors LLC (2.41%), Victory Capital Management Inc. (1.84%), Victory Capital Management Inc. (1.48%), Eagle Asset Management Inc. (1.42%), Geode Capital Management LLC (1.38%) and Charles Schwab Investment Management Inc. (0.77%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Champlain Investment Partners LLC, Victory Capital Management Inc., Thrivent Financial for Lutherans, AQR Capital Management LLC, Eagle Asset Management Inc., Fort Washington Investment Advisors Inc. OH and Alliancebernstein L.P.. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive.

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Panagora Asset Management Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Copper Rock Capital Partners LLC, WCM Investment Management LLC, Bank of Montreal Can and UBS Group AG. View Insider Buying and Selling for NuVasive.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NUVA stock can currently be purchased for approximately $75.16.

NuVasive has a market capitalization of $3.91 billion and generates $1.17 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.47 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.

The official website for NuVasive is http://www.nuvasive.com/.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]